You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
At the AACR annual meeting last week researchers presented new data on a range of technologies, discussed novel platforms, compared existing tools, and explored new clinical uses.
Presenters highlighted early work that supports the push for a national, systematic effort to elucidate progression from precancerous states to clinical malignancy.
In 19,000 cases reported so far, researchers have gleaned data that enhances understanding of the spectrum of cancer mutations and supports the rationale of ongoing basket trial initiatives.
Johns Hopkins University researchers have developed a method called targeted error correction sequencing, or TEC-Seq, to increase liquid biopsy sensitivity.
One speaker cited the success of screening Ashkenazi Jewish women for BRCA mutations, but another said extending testing to a wider population could be harder.
Such analyses can help researchers pinpoint how various cancers evolve and determine the best kinds of tests to use to find certain disease information.
Speakers at the conference's opening plenary showed how their work in cancer research fit into the broad theme of 'Discover, Predict, Prevent, Treat.'
The database is intended to provide the research community with a resource of control cases to aid in the evaluation of variants of unknown significance in breast cancer.
Representatives from industry, academia, the FDA, and insurance companies gathered for a joint FDA- and American Association for Cancer Research-sponsored workshop.
The VP lauded the work of the assembled researchers, offered suggestions for ways forward, and asked for their help in determining how to change the system for the better.